Side Effects & Safety AOD-9604 has a favorable safety profile supported by clinical trial data: FDA GRAS status: The compound received GRAS status as a food ingredient, reflecting some regulatory safety evaluation, though this is not equivalent to drug safety approval Clinical trial tolerability: Phase I and Phase II clinical trials conducted by Metabolic Pharmaceuticals generally found AOD-9604 well-tolerated at studied doses Injection site reactions: Minor discomfort with subcutaneous administration Headache and nausea: Reported in some clinical trial subjects No significant metabolic effects: Blood glucose, insulin, HbA1c, and IGF-1 were not significantly altered in clinical studies, which distinguishes it favorably from full GH Long-term safety data for subcutaneous use in the research community context (typically higher and more frequent dosing than clinical trials) is limited
i samo na temelju jedne ili vie pravnih osnova navedenih u lanku 6
18% of US respondents reported taking prescription drugs for weight loss in 2025, up from 10% in 2024 Source: Euromonitors Voice of the Consumer: Health and Nutrition Survey, fielded February 2024 Legacy weight loss brands turn their attention towards GLP-1 consumers Heritage weight loss companies are shifting focus to accommodate the GLP-1 consumer
4750 To date, there has only been 1 randomized crossover study to investigate comparative effects of different medications for management of PBH after RYGB, using mixed meal tolerance test and CGM
More Info Our Infusion (IV) Compound Descriptions Vitamin C Essential for collagen production, immune function, wound healing, iron absorption and antioxidant protection
